ELEVATED LEVELS OF PLASMIN AND SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR PREDICT THE RISK OF ISCHEMIC HEART DISEASES

Adel Nasser Kahun1, Anwar Jasib Almzaiel2*

Abstract

Background: Ischemic heart disease (IHD) is one kind of cardiovascular disease (CVD) disorder that occurs when the heart does not get an adequate supply of blood. The Plasminogen (Plg) activator Plasmin (Pm) System is an example of a carefully controlled proteolytic system that plays an important part in fibrinolysis and thrombosis. The soluble version of the membrane-bound receptor uPAR is called soluble urokinase plasminogen activator receptor, or suPAR for short. Aim: To determine whether the level of Plasmin and suPAR are related to the risk of IHD. Methods: A case-control study was performed between October 2021 to July 2022. One hundred twenty individuals were enrolled, 60 patients with IHD (MI=30,angina=30) and mean age (60.7±2.06). Sixty healthy subjects served as a healthy control group, with mean age (of 48.7±0.86; 15 female, 45 male). Plasmin and suPAR serum concentrations were determined using an ELISA. Results: The findings showed that patients with IHD had substantially higher blood levels of plasmin and suPAR than those in the control group (P < 0.01). Conclusions: An increase in plasmin and suPAR levels is associated with IHD risk factors, which suggest them as biomarkers for IHD diagnosis and progress.

Keywords:

:Plasmin, Soluble urokinase plasminogen activator receptor, and ischemic heart diseases.


Full Text:

PDF


References


1. P. B. Lockhart and Y. Sun, “Diseases of the cardiovascular system,” Burket’s Oral Med., pp. 505–552, 2021. 2. P. Kasper et al., “NAFLD and cardiovascular diseases: a clinical review,” Clin. Res. Cardiol., vol. 110, no. 7, pp. 921–937, 2021. 3. H. E. Bays, “Ten things to know about ten cardiovascular disease risk factors (‘ASPC Top Ten–2020’),” Am. J. Prev. Cardiol., vol. 1, p. 100003, 2020. 4. X. Fu, Q. Liu, X. Zeng, S. Huang, R. Huang, and Q. Gao, “Association between cerebral arterial stiffness and large artery atherosclerosis in acute ischemic stroke,” J. Stroke Cerebrovasc. Dis., vol. 27, no. 11, pp. 2993–3000, 2018. 5. P. Libby et al., “Lewis EF,” Atheroscler. Nat. Rev. Dis. Prim., vol. 5, no. 1, p. 56, 2019. 6. C. Cayrol and J. Girard, “Interleukin‐33 (IL‐33): a nuclear cytokine from the IL‐1 family,” Immunol. Rev., vol. 281, no. 1, pp. 154–168, 2018. 7. M. W. Dahlgren et al., “Adventitial stromal cells define group 2 innate lymphoid cell tissue niches,” Immunity, vol. 50, no. 3, pp. 707–722, 2019. 8. P. Raggi et al., “Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions,” Atherosclerosis, vol. 276, pp. 98–108, 2018. 9. A. Anfray et al., “Single-and two-chain tissue-type plasminogen activator treatments differentially influence cerebral recovery after stroke,” Exp. Neurol., vol. 338, p. 113606, 2021. 10. R. B. Alsina and L. I. Mukhametova, “Structure and function of plasminogen/plasmin system,” Russ. J. Bioorganic Chem., vol. 40, no. 6, pp. 590–605, 2014. 11. P. Jirak et al., “A Comparative Analysis of Novel Biomarkers in Sepsis and Cardiovascular Disease,” Appl. Sci., vol. 12, no. 3, p. 1419, 2022. 12. G. Isola, A. Polizzi, A. Alibrandi, R. C. Williams, and R. Leonardi, “Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase‐type plasminogen activator receptor (suPAR) levels,” J. Periodontol., vol. 92, no. 6, pp. 896–906, 2021. 13. F. Napolitano and N. Montuori, “The role of the plasminogen activation system in angioedema: Novel insights on the pathogenesis,” J. Clin. Med., vol. 10, no. 3, p. 518, 2021. 14. M. C. Drinane, J. A. Sherman, A. E. Hall, M. Simons, and M. J. Mulligan‐Kehoe, “Plasminogen and plasmin activity in patients with coronary artery disease,” J. Thromb. Haemost., vol. 4, no. 6, pp. 1288–1295, 2006. 15. A. G. Bharadwaj, R. W. Holloway, V. A. Miller, and D. M. Waisman, “Plasmin and plasminogen system in the tumor microenvironment: implications for cancer diagnosis, prognosis, and therapy,” Cancers (Basel)., vol. 13, no. 8, p. 1838, 2021. 16. Y. Shen, “Plasminogen: a novel inflammatory regulator that promotes wound healing.” Umeå University, 2013. 17. Tuama, A. N., Abbas, K. H., Hamzah, M. Q., Jabbar, A. H., & Agam, M. A. (2020). An Overview on Characterization of Silver/Cuprous Oxide Nanometallic (Ag/Cu2O) As Visible Light Photocatalytic. International Journal of Advanced Science and Technology, 29(03), 5008-5018. 18. Mezan, S. O., Jabbar, A. H., Hamzah, M. Q., Tuama, A. N., Hasan, N. N., & Agam, M. A. (2018). Synthesis and Characterization of Zinc Sulphide (ZnS) Thin Film Nanoparticle for Optical Properties. Journal of Global Pharma Technology, 10(07), 369-373. 19. L. J. H. Rasmussen, J. E. V. Petersen, and J. Eugen-Olsen, “Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation,” Front. Immunol., vol. 12, 2021. 20. H. Enocsson et al., “Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus,” J. Autoimmun., vol. 106, p. 102340, 2020. 21. T. Skalec, B. Adamik, K. Kobylinska, and W. Gozdzik, “Soluble Urokinase-Type Plasminogen Activator Receptor Levels as a Predictor of Kidney Replacement Therapy in Septic Patients with Acute Kidney Injury: An Observational Study,” J. Clin. Med., vol. 11, no. 6, p. 1717, 2022. 22. M. Persson, G. Engström, H. Björkbacka, and B. Hedblad, “Soluble urokinase plasminogen activator receptor in plasma is associated with the incidence of CVD. Results from the Malmö Diet and Cancer Study,” Atherosclerosis, vol. 220, no. 2, pp. 502–505, 2012. 23. D. J. Eapen et al., “Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and future adverse events,” J. Am. Heart Assoc., vol. 3, no. 5, p. e001118, 2014. 24. S. Botha, C. M. T. Fourie, R. Schutte, J. Eugen-Olsen, R. Pretorius, and A. E. Schutte, “Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population,” Int. J. Cardiol., vol. 184, pp. 631–636, 2015. 25. J. Chew-Harris, S. Appleby, A. M. Richards, R. W. Troughton, and C. J. Pemberton, “Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals,” Clin. Biochem., vol. 69, pp. 36–44, 2019.

Refbacks

  • There are currently no refbacks.